TEL AVIV, Israel, September 22, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. SPRC (“Company” or “SciSparc”), a clinical-stage specialty pharmaceutical company focused on developing therapies to treat central nervous system disorders, today announced that Clearmind Medicine Inc. (“Clearmind”) ID, CMNDF, CWYhas filed a provisional patent application related to metabolic syndromes, including obesity, regarding the company’s collaboration with Clearmind.

The patent filing is the third of the collaborations, each covering SciSparc’s proprietary combination of palmitoylethanolamide (PEA), the active ingredient in its proprietary CannAmid™ (used to treat obesity and related metabolic disorders), and Clearmind’s MEAI, a novel proprietary psychedelic treatment relates to various addictions and based on research at the Hebrew University.

“Our collaboration with Clearmind is focused on treating various addictive and eating behaviors, taking advantage of our technology and that of Clearmind. Obesity, overweight and binge eating are among the biggest health problems of the last decade and are associated with addictive behaviors, and yet the treatment options available on the market are very limited,” commented Oz Adler, Chief Executive Officer of SciSparc. “We believe that the combination of MEAI with SciSparc’s CannAmide™ could present a great opportunity to treat these conditions.”

About SciSparc Ltd SPRC:

SciSparc Ltd. is a specialty clinical stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following THC and/or non-psychoactive cannabidiol (CBD)-based drug development programs: SCI-110 for the treatment of Tourette’s syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for pain management; and SCI-210 for the treatment of…